Northwestern University Feinberg School of Medicine
Mesulam Center for Cognitive Neurology and Alzheimer’s Disease
Skip to main content

Study Details

Alzheimer’s Disease Neuroimaging Initiative 3
The overall goal of ADNI3 is to determine the relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as the pathology evolves from normal aging through very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNI3 continues the previously funded AD Neuroimaging Initiative (ADNI1, ADNI-GO, and ADNI-2), and remains a public/private collaboration between academia and industry to study biomarkers of AD. ADNI will continue to inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios. This is a non-randomized natural history non-treatment study. Participants will need to be 55 - 90 years, otherwise healthy with no neurologic disease such as Alzheimer's disease. Approximately 1070 - 2000 participants will be enrolled at approximately 59 sites in the United States and Canada. Approximately, 700 - 800 will be rollover participants from previous ADNI studies, and 370 - 1200 will be newly enrolled. Clinical/cognitive, imaging, biomarker, and genetic characteristics will be assessed across the three cohorts. Subjects will undergo longitudinal clinical and cognitive assessments, computerized cognitive batteries, biomarker and genetic tests, PET (FDG, amyloid and tau) and MRI scans and cerebral spinal fluid (CSF) collection for up to 5 years.
- No history of major psychiatric disorders such as major depression, bipolar disorder, or schizophrenia.
- Must be between the ages of 55-90 years (inclusive).
- Must have a study partner who has frequent contact with the participant (i.e., minimum average of 10 hours per week) and is available to accompany the participant to all clinic visits for the duration of the protocol.
- Must have visual and auditory acuity adequate for neuropsychological testing.
- Must be in good general health with no diseases expected to interfere with the study.
- For females only: Participant is not pregnant, lactating, or of childbearing potential (i.e. women must be two years post-menopausal or surgically sterile).
- Must be willing and able to participate in a longitudinal imaging study lasting up to 5 years.
- Must have completed six grades of education or has a good work history (sufficient to exclude mental retardation).
- Must speak English fluently.
- Must be willing to undergo repeated MRIs (3Tesla) and at least two PET scans - must not have any MRI contraindications (i.e. pacemaker, claustrophobia)
- Must agree to collection of blood for genomic analysis (including GWAS (genome-wide association study) sequencing and other analysis), APOE (Apolipoprotein E) testing and biospecimen banking.
- Must agree to collection of blood for biomarker testing.
- Must agree to at least one lumbar puncture for the collection of CSF.
- Must agree to share genomic data and biomarker samples.
Rogalski, Emily JoyRogalski, Emily Joy
NCT02854033 STU00203359
More Info

For more information on this study please contact us:

Study Coordinator 312 503 5212
Back to top

Follow Mesulam Center on